Please login to the form below

Not currently logged in
Email:
Password:

Ronald Berenson to lead Aequus BioPharma

Joins the Cell Therapeutics subsidiary as president and CEO

Cell Therapeutics' US subsidiary Aequus BioPharma has appointed Ronald Berenson as president and CEO.

In his new role he will be tasked with expanding Washington State-based Aequus' GlycoPolymer technology, which aims to create novel biopharmaceuticals with improved pharmacokinetic properties that require less frequent injections than current treatments.

Berenson said: "There are more than 100 therapeutic proteins on the market, and they represent one of the fastest growing classes of drugs today. Patient convenience and compliance continue to be issues with therapeutic proteins due to the need for frequent injections.

"I believe that Aequus's novel approach could address these challenges with the potential to be applied to a wide spectrum of therapeutics."

Berenson, who was most recently an Entrepreneur in Residence at the University of Washington, has spent more than 20 years in senior biotech management roles.

During this time he co-founded HemaQuest Pharmaceuticals, serving as president and CEO for its first three years, and founded the oncology-focused biotech companies Xcyte Therapies and CellPro.

11th December 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics